Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
Conditions
Interventions
None listed
Sponsors
Sam Sabinsa Group Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Participants should be willing to give a written informed consent. 2.Participants should be willing to comply with the requirements of the trial/ study. 3.Male and female participants aged between 25-65 years. 4.Females with childbearing potential who agree to use a barrier method of contraception throughout the study period. 5.Participants, newly diagnosed with Type 2 Diabetes (T2DM) and is drug naive with FBS between 126 to 210 mg/dL, PPBS between 200 to 300 mg/dL and HbA1c between 6.5 to 8.9 %. 6.Lipid parameters: Total Cholesterol between 200 to 300 mg/dL, Triglyceride between 160 to 300 mg/dL and LDL between 120 to 200 mg/dL. 7.Ability to swallow and retain oral medications as per the protocol.
Exclusion criteria
Exclusion criteria: 1. History of Smoking and Alcohol intake (within 3 months before screening) 2. Type-1 Diabetes 3. Presence of chronic gastrointestinal diseases, severe immune deficiencies, lactose intolerance. 4. Use of any lipid lowering therapies in the past 3 months. 5. Patients on antihypertensive medications. 6. Patient with history of clinically significant thyroid disorder, gastrointestinal, cardiovascular, haematological, hepatic, renal, respiratory, active malignancies or genitourinary abnormalities or diseases. 7. Patient who has participated in any clinical trial within the past 3 months. 8. Pregnant and lactating women and those not willing to follow a reliable and effective contraceptive measure during the study. 9. Any planned surgery during the study. 10. A history of significant multiple and/or severe allergies or anaphylactic reactions. 11. Patient with known history of hypersensitivity to the investigational product. 12. Participant who has participated in any clinical trial within the last 3 months. 13. Any other condition that the Principal Investigator thinks may jeopardize the study. 14. Any other reason(s) as per principal investigator discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of Beta Amyrin Palmitate on blood glucose level. 1. Mean change in HbA1c from screening to final visit. 2. Mean change in fasting blood glucose & postprandial blood sugar from screening to final visit.Timepoint: 1. Screening to 90 days 2. Screening to 90 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare Mean change in lipid profile- Triglycerides, low density lipid, very low-density lipid, high density lipid & total cholesterol. 2. To compare the mean change in HbA1c, Fasting Blood Glucose and Post-prandial blood sugar. 3. To compare the glucose tolerance (OGTT). 4. Safety is determined based on the tolerance to Beta Amyrin Palmitate without any incidence of adverse events. Study compliance without drop-outs. No adverse change in complete blood count, urine routine and microscopic blood biochemistry, and incidence of any adverse events during the study period in both the arms.Timepoint: 1. Screening to 90 days 2. Screening to 90 days 3. Day-1 to 90 days 4. Screening to 90 days | — |
Countries
India
Contacts
Public ContactSatish G
Sami Sabinsa Group Limited
Outcome results
None listed